Form 4: Whitehawk Therapeutics Director Caley Castelein Granted Stock Options

Whitehawk Therapeutics, Inc. director Caley Castelein was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Summary

• Caley Castelein, a Director of Whitehawk Therapeutics, Inc. (WHWK), was granted 40,006 stock options.
• The options have an exercise price of $2.04 per share.
• The grant date for these options is June 12, 2025.
• The options are subject to a vesting schedule where 100% of the shares will vest on the earlier of the one-year anniversary of the grant date (June 12, 2026) or the day immediately prior to the next annual meeting of stockholders following the grant date, contingent on continued service as a Service Provider.
• The options have an expiration date of June 12, 2035.
• Following this transaction, Caley Castelein beneficially owns 40,006 derivative securities directly.
• The filing also includes a Power of Attorney granted by Caley Castelein on April 25, 2025, authorizing specific individuals to prepare, execute, and submit SEC reports on their behalf.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive event for the individual and generally viewed as a neutral to slightly positive corporate governance practice as it aligns interests. It does not indicate significant positive or negative news for the company's immediate financial performance.

Positives

• The grant of stock options aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• The vesting schedule encourages continued service and long-term commitment from the director.

Risks

• The vesting of the stock options is contingent upon Caley Castelein continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date.

Future Outlook

The stock options granted to Director Caley Castelein are subject to a vesting schedule, with full vesting expected on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, provided the director continues as a service provider.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all industries for publicly traded companies. The grant of stock options is a standard component of executive and director compensation packages, designed to align their interests with long-term shareholder value, particularly in sectors like biotechnology or pharmaceuticals where long development cycles are common.

Corporate Governance

Related Party Transactions

• The grant of 40,006 stock options to Caley Castelein, a Director of Whitehawk Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Management: The Power of Attorney simplifies SEC compliance for the director and the company's legal/compliance team.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the day immediately prior to the next annual meeting of stockholders following the grant date, contingent on continued service.
• The options can be exercised at any time after vesting until their expiration on June 12, 2035.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Stock Options, Director Compensation, SEC Form 4, Equity Incentive Plan, Executive Compensation, Corporate Governance, Insider Transaction, Vesting Schedule